Gain Therapeutics (GANX) announced the start of the Phase 1b extension study allowing participants to continue treatment for an additional nine months. More than half of the participants have agreed to continue treatment. The Phase 1b study enrolled 21 participants and is expected to complete in December 2025. Early data from the Phase 1b study will be presented on October 7, 2025, at the International Congress of Parkinson’s Disease and Movement Disorders(R) in Honolulu, HI. Additional 90-day analysis from participants enrolled as of June 30, 2025, including functional changes scored according to the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) as well as biomarker data from cerebrospinal fluid and blood, will be available as expected in Q4 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Positive Buy Rating for Gain Therapeutics Driven by Promising Clinical Trial Developments and Strong Financial Outlook
- Promising Developments and Regulatory Milestones Bolster Buy Rating for Gain Therapeutics
- Gain Therapeutics receives Australian approval of Phase 1b dosing extension
- Buy Rating Reaffirmed for Gain Therapeutics Amid Promising Clinical Developments and Strong Financial Positioning
- Gain Therapeutics Reports Q2 2025 Financial Results